Resources
The latest in from biologics discovery and development through to production and supply chain management.
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Oligonucleotides
Japanese Team Successfully Skip Abnormal Gene In Vitro With Antisense Oligonucleotide for BPAN
Rare disease BPAN currently has no treatment options, this new research investigates whether antisense oligonucleotide therapies could be the answer to address this unmet need.
Oligonucleotides
Oligo Sequencing Technologies - What Methods and Techniques Are Utilized in the Pharmaceutical Industry?
Oligo sequencing revolutionizes biologics research, ensuring accurate analysis of oligonucleotides. Biologics by Oxford Global explores methods, safety, sustainability, and future trends. Despite challenges, advancements promise exciting opportunities for scientific discovery.
Oligonucleotides
Innovation at the Crossroads: Oligonucleotide Therapeutics and the Evolution of Drug Design
Can oligonucleotide therapeutics shape the future of healthcare? We journey through AI frontiers, sustainable synthesis, and regulatory challenges.
Oligonucleotides
Sustainability in Pharmaceutical Manufacture and Healthcare Provision
How do things stand with sustainability in pharmaceutical manufacture at present? What are some members of the industry doing to reduce their carbon footprint?
Oligonucleotides
New Approach to Oligo-Peptide Synthesis from Novo and Aarhus University
The collaboration could unlock the more cost-effective synthesis of oligonucleotide-peptide conjugates.
Oligonucleotides
How Do Regulatory Considerations Impact the Clinical Development of Oligonucleotide Therapies?
What are the regulatory considerations that need to be made in the clinic for oligonucleotide therapies? What's the existing guidance for this emerging modality?
Oligonucleotides
Friedrich Miescher: The Pioneer of Nucleic Acid Discovery
As medical research that is founded on nucleic acids continues to progress, we take a step back to look at the man who first discovered nucleic acids.
Oligonucleotides
The Growing Potential for Antisense Oligonucleotide Therapy
Antisense oligonucleotides hold major promise in future patient treatment approaches. Through targeting RNA to regulate protein expression, they can help to address diseases at their source and advance therapeutic outcomes.
Oligonucleotides
Targeted Delivery with FORCE: Novel Approaches in Oligo Therapeutics
How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.
Oligonucleotides
Transforming Oligonucleotide Manufacturing: A Transformative UK Collaboration
A new collaboration from the Medicines Manufacturing Innovation Centre is looking to change the face of oligonucleotide development.
Oligonucleotides
Refractive Index Paves the Way to Greener Peptide and Oligonucleotide Synthesis
John Lopez of Novartis discusses the more sustainable possibilities refractive index monitoring offers in SPPS and SPOS.
Oligonucleotides
The Complex Case of Antisense Oligonucleotides
We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.
Oligonucleotides
Sustainable Synthesis of Therapeutic Oligonucleotides
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.
Oligonucleotides
Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine
With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality?
Oligonucleotides
Oligonucleotide Chemistry & Therapeutics Symposium: Market Trends and Industry Challenges
The first of its kind, the Oligonucleotides: Chemistry & Therapeutics Symposium was a hit. We sat down with an advisory group of leading industry experts to hear their thoughts on the future of the Oligonucleotide drug industry as well as some of its key market trends and challenges.
Oligonucleotides
Characterisation of Therapeutic Oligonucleotides in Early Drug Discovery
Oligonucleotides are fast becoming a globally recognised form of therapeutic treatment. But how easy is it to analyse them? Director of AstraZeneca, Tomas Leek takes us through the analytic challenges of the early-stage oligonucleotide characterisation.
Subscribe to Our Newsletter
Sign up for our monthly newsletter to
keep up with all things biologics